Background: Hyperbaric oxygen therapy has been demonstrated to lower blood glucose levels in patients with diabetes. Continuous glucose monitoring (CGM) allows glucose monitoring in real time. Battery-operated CGM transmitters have yet to be formally tested and given safety approval for use in a hyperbaric environment.
Materials And Methods: We evaluated and tested commercially available Dexcom® G6 CGM transmitters under hyperbaric conditions. Each transmitter contains a 3V, 130-mAh (0.39 Wh) lithium manganese dioxide battery (IEC CR1632) and circuit board that are fully encapsulated in epoxy. Each transmitter is pressurized to 90 pounds per square inch (psi) in an autoclave at 40°C for up to 72 hours during manufacturing to ensure that all enclosed air spaces are eliminated from the epoxy. We compared the CGM components against section 14.2.9.3.17.5 of the 2018 National Fire Protection Association 99 (NFPA 99) Health Care Facilities Code requirements. Six CGM transmitters attached to estimated glucose value generators (EGVGs) underwent 11 pressurization cycles to 45 feet of seawater (fsw). All transmitters were returned to the manufacturer to assess post-exposure structural integrity. G6 sensors, which contain no electrical components or compressible air spaces, do not pose a risk in the hyperbaric environment.
Results: There was no observed change in preset EGVG readings during hyperbaric exposures. Post-exposure testing revealed no structural compromise after repeated hyperbaric exposures.
Conclusions: The CGM transmitter meets section 14.2.9.3.17.5 of the 2018 NFPA 99 requirements for battery-operated devices allowed for use in a hyperbaric environment. This analysis revealed no significant safety concerns with subjecting Dexcom G6 CGM transmitters to hyperbaric environments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.22462/01.03.2020.2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility, Acceptability, and Validity of Home Continuous Glucose Monitoring-Based Oral Glucose Tolerance Test in Youth.
J Clin Endocrinol Metab
December 2024
Center for Pediatric Research in Obesity and Metabolism and Division of Pediatric Endocrinology, Diabetes, and Metabolism, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Context: Home-based approaches to type 2 diabetes (T2D) screening in youth may facilitate early diagnosis.
Objective: To evaluate feasibility, acceptability, and validity of a continuous glucose monitoring (CGM)-based oral glucose tolerance test (OGTT).
Design: Prospective observational study.
This article discusses the life of a Type 1 diabetic. Everything is a danger. Stress, flu, infection, or a common cold could all lead to a hospital stay.
View Article and Find Full Text PDFWhat Is the Influence of HIV Serostatus on HbA1c? A Prospective Analysis Using Continuous Glucose Monitoring.
Diabetes Care
August 2024
Brighton and Sussex Medical School, Brighton, East Sussex, U.K.
Article Synopsis
- - The study aimed to explore whether living with HIV affects HbA1c levels in individuals, especially given that Type 2 diabetes is more prevalent in people living with HIV.
- - Researchers compared 60 participants with HIV and 48 HIV-negative participants, assessing their glucose levels and HbA1c through various tests and models.
- - Findings showed that HIV status did not significantly impact HbA1c levels, suggesting that HbA1c can be reliably included in regular clinical assessments for people living with HIV.
Impact on diabetes control and patient-reported outcomes of a newer implantable continuous glucose monitoring system (Eversense® CGM System): a single-centre retro- and prospective observational study.
Swiss Med Wkly
March 2024
Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine, Luzerner Kantonsspital, Luzern, Switzerland.
Aims Of The Study: The Eversense® CGM System is the first and only continuous glucose monitoring system (CGMS) that uses a fully subcutaneous implanted sensor. This study aimed to evaluate effectiveness, safety and patient-reported outcomes in patients using the Eversense® CGM System in a realistic clinical setting, assessed at a single Swiss diabetes centre (Luzerner Kantonsspital) with prolonged follow-up.
Methods: This was a prospective and retrospective observational study that included patients with type 1 diabetes mellitus in whom at least one Eversense® glucose sensor was implanted between 2017 and 2022.
(Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise.
Diabetes Technol Ther
December 2023
University of Bayreuth, 26523, Division Exercise Physiology and Metabolism Institute of Sport Science, Universitätsstraße 30, Bayreuth, Bayern, Germany, 95440;
Physical activity and exercise have many beneficial effects on general and type 1 diabetes (T1D) specific health and are recommended for individuals with T1D. Despite these health benefits, many people with T1D still avoid exercise since glycemic management during physical activity poses substantial glycemic and psychological challenges - which hold particularly true for unannounced exercise when using an AID system. Automated insulin delivery (AID) systems have demonstrated their efficacy in improving overall glycemia and in managing announced exercise in numerous studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!